Agree. Prove the thesis with IIH, stick to the strong moat of the orphan drug designation and then spruik your Intracranial Pressure lowering abilities in other conditions to unlock the blue sky valuation.
I disagree that IIH is too small for Big Pharma - an unencumbered TAM of $1.6B is highly lucrative. Throw in the scope for opening up additional listings in other indications and this will set off a bidding war that Loveridge will expertly manage.
Ann: Notice of Investor Call and Presentation, page-130
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
